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Severe combined immunodeficiency (SCID), the most severe form of T-cell
immunodeficiency, can be screened at birth by quantifying T-cell receptor excision
circles (TRECs) in dried blood spot (DBS) samples. Early detection of this condition
speeds up the establishment of appropriate treatment and increases the patient’s life
expectancy. Newborn screening for SCID started in January 2017 in Catalonia, the first
Spanish and European region to universally include this testing. The results obtained in
the first 2 years of experience are evaluated here. All babies born between January 2017
and December 2018 were screened. TREC quantification in DBS (1.5mm diameter)
was performed with the Enlite Neonatal TREC kit from PerkinElmer (Turku, Finland). In
2018, the retest cutoff in the detection algorithm was updated based on the experience
gained in the first year, and changed from 34 to 24 copies/µL. This decreased the retest
rate from 3.34 to 1.4% (global retest rate, 2.4%), with a requested second sample rate
of 0.23% and a positive detection rate of 0.02%. Lymphocyte phenotype (T, B, NK
populations), expression of CD45RA/RO isoforms, percentage and intensity of TCR αβ
and TCR γδ, presence of HLA-DR+ T lymphocytes, and in vitro lymphocyte proliferation
were studied in all patients by flow cytometry. Of 130,903 newborns screened, 30
tested positive, 15 of which were male. During the study period, one patient was
diagnosed with SCID: incidence, 1 in 130,903 births in Catalonia. Thirteen patients
had clinically significant T-cell lymphopenia (non-SCID) with an incidence of 1 in 10,069
newborns (43% of positive detections). Nine patients were considered false-positive
cases because of an initially normal lymphocyte count with normalization of TRECs
between 3 and 6 months of life, four infants had transient lymphopenia due to an initially
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low lymphocyte count with recovery in the following months, and three patients are still
under study. The results obtained provide further evidence of the benefits of including
this disease in newborn screening programs. Longer follow-up is needed to define the
exact incidence of SCID in Catalonia.
Keywords: newborn screening, severe combined immunodeficiency, T-cell receptor excision circles, T-cell
receptor, T-lymphocytes, stem cell transplantation
INTRODUCTION
Newborn screening (NBS), initially implemented in the
United States in 1961 (1), has been available in most developed
countries for decades, originally for the detection and early
treatment of phenylketonuria and now for other endocrine and
metabolic diseases, mainly using tandem mass spectrometry.
DNA-based testing for other diseases has been only recently
included in the NBS programs of some countries. Since
its initial implementation in Wisconsin in 2008, NBS for
severe combined immunodeficiency (SCID) using a T-cell
receptor excision circle (TREC) assay has been established
worldwide, including in most of the United States (2), Taiwan
(3), Israel (4), New Zealand, some Canadian regions (2),
Norway (5), and Catalonia (Spain). Previously published
results showed an incidence of SCID of around 1 in 56,000
newborns (5, 6) and a high survival rate (92%) after appropriate
treatment (2).
SCID, the most severe form of T-cell primary
immunodeficiency (PID), includes a group of inherited defects
characterized by severe T-cell lymphopenia (TCL). Patients with
SCID require prompt clinical intervention to prevent severe
life-threatening infections, and several studies have reported
significantly improved survival in babies diagnosed at birth
(7, 8). Curative treatment is based on hematopoietic stem cell
transplantation (HSCT) or gene therapy when available (8).
SCID can be screened at birth in a cost-effective way on a large
scale through quantification of T-cell receptor excision circles
(TRECs) in Guthrie card dried blood spot (DBS) samples (9, 10).
SCID newborn screening can also identify other clinically
relevant forms of TCL, which have an overall incidence of 1
in 7,300 newborns (2). These include specific syndromes such
as 22q11 deletion (DiGeorge) syndrome, Down syndrome, and
CHARGE syndrome among others (11, 12).
TRECs are circular DNA molecules formed by T-cell receptor
gene rearrangement during the normal process of T-cell
differentiation in the thymus. TRECs do not undergo further
replication in dividing cells. Hence, they are stable circular DNA
fragments, which are a useful marker of recently formed T-cells,
a cell population that is extremely low in newborns with SCID.
TREC copy number can be determined using a quantitative
PCR-based method with time-resolved fluorescence resonance
energy transfer (TR-FRET)-based detection in eluted DNA
from routinely collected DBS (9). Kappa-deleting recombination
excision circles (KRECs), the circular by-product of B cell
immunoglobulin kappa gene rearrangement, have been proposed
for a combined TREC-KREC screening approach (13). This
could also enable the early detection of patients with severe
forms of B cell deficiency, such as X-linked agammaglobulinemia
(XLA) (14).
The implementation of screening through TREC assays
provides the earliest possible identification and allows for
prompt, successful transplantation before infants experience
severe infection, organ damage, and, ultimately, death (15).
The cost-effectiveness of including SCID in NBS programs
has been demonstrated in the United States (16, 17) and
Europe (6, 10, 18, 19).
In Catalonia, the NBS program started with phenylketonuria
detection in 1969 and congenital hypothyroidism in 1982.
Today, around 67,000 newborns per year are screened for
24 diseases (phenylketonuria, congenital hypothyroidism, cystic
fibrosis, sickle cell disease, aminoacidopathies, organic acidurias,
mitochondrial beta-oxidation disorders, and, lately, SCID). SCID
was included in the Catalonian NBS program in January 2017,
and data from the first 24 months following its implementation
are presented here.
MATERIALS AND METHODS
Population and Data Collection
All consecutive DBS samples received as part of the universal
NBS program in Catalonia between January 2017 and December
2018 were analyzed (n = 130,903). Samples with the following
characteristics were excluded: collection time before 44 h or after
7 days of life, transfusions, poor DNA amplification, and poor
quality or blood amount. Ultimately, this study was performed in
129,614 newborns.
Demographics (birth date, date of sample collection, parents’
origin, newborn sex, gestational age, and birth weight) were
electronically collected. Extremely preterm newborns were
defined as those with a gestational age <32 weeks, preterm
newborns ≥32 and <37 weeks, and term newborns ≥37 weeks.
Low birth weight in term babies was defined as <2,500 g and
normal birth weight as ≥2,500 g.
From 1 January to 30 June 2017, newborns (n = 33,040)
underwent SCID screening as part of a 6-month prospective
implementation pilot study that validated our approach.
However, in January 2018, we decided to update the decision
algorithm (Figure 1), lowering the retest cutoff from 34 to
24 copies/µL. The results from newborns screened in 2018
were then evaluated (n = 64,092; 63,393 after applying
exclusion criteria).
The study was approved by the Government of Catalonia
(Departament de Salut, Generalitat de Catalunya) for its NBS
program. Specific informed consent was obtained from all
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FIGURE 1 | SCID NBS detection decision algorit hm. *The retest cutoff was changed from 34 to 24 copies/µL in 2018. **If beta-actin gene <50 copies/µL a second
sample was requested because the sample was considered of unsatisfactory quality. TRECs, T-cell receptor excision circles.
individual participants included in the study whose genetic
evaluation was needed.
Sample Testing
Quantification of TRECs in DBS (1.5-mm diameter spot)
was performed according to the commercial Enlite Neonatal
TREC kit instructions (PerkinElmer, Turku, Finland). The
EnLite TREC kit is a combination of PCR-based nucleic acid
amplification and time-resolved fluorescence resonance energy
transfer (TR-FRET)-based detection. The assay detects two
targets simultaneously: TRECs and beta-actin, which is used
as the internal control to monitor specimen amplification in
each test.
DBS punches were directly inserted in 96-well PCR plates
using a Wallac DBS puncher (PerkinElmer). DNA was eluted in
the first step, and the second step involved PCR amplification
of TRECs and beta-actin as well as hybridization with target
sequence-specific probes. The PCR plate was then read in a
Victor EnLite fluorometer (PerkinElmer). A full calibration curve
with blanks and three DBS calibrators was run in triplicate on
each plate. A low-TREC control, a no-TREC control, a high-
TREC control, and a blank paper disk (with no blood content)
were used as quality controls in each plate. Interpretation of the
assay results uses fluorescence counts measured at 615, 665, and
780 nm. Corrected fluorescence counts, TREC responses, and
beta-actin responses for all reactions were calculated from the
raw fluorescence counts. Calibrator responses were fitted against
the ArcSinh transformed concentrations (copies/µL) using
unweighted linear regression. The Enlite software generated a
calibration curve and the sample and DBS control concentrations
(copies/µL) in each run.
Definition and Interpretation of Results
Before implementing the protocol, the method was verified
(repeatability, reproducibility, limit of detection, limit of
quantification, sensitivity, and specificity) and these parameters
were successfully compared with those stated in the kit
insert (Supplementary Material S1). In addition, available NBS
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FIGURE 2 | Immunological and genetic protocol in positive cases. 1Flow cytometry protocols are shown in Supplementary Material S5; 2Lymphopenia and SCID
criteria are shown in Supplementary Material S2; 3AFP values are not reliable before 12 months of age; therefore, AFP was only studied in patients older than one
year lacking an alternative diagnosis; 4The list of 323 PID genes is shown in Supplementary Material S3. AFP, alpha-fetoprotein; ATM, ataxia telangiectasia; B,
B-cells; CMV, cytomegalovirus; Ig, immunoglobulin; NK, natural killer cells; PID, Primary immunodeficiency; SCID, severe combined immunodeficiency; T, T-cells; TCR,
T-cell receptor; TRECs, T-cell receptor excision circles.
samples from children with a known SCID diagnosis in Catalonia
in the last 5 years were analyzed as positive controls (n = 6;
median, range TREC copies/µL: 2, 2–4), as well as five other
positive samples from the SCID Newborn Screening Quality
Assurance Program-Proficiency Testing Program provided by
the CDC (Centers for Disease Control and Prevention,
Atlanta, USA).
After reviewing the decision algorithms from other NBS
programs with previous experience of this disease, we decided to
start the pilot study with the algorithm used by Audrain et al. (6),
which had a threshold of >34 copies/µL (Figure 1).
Samples whose TREC value was ≤34 copies/µL were retested
in duplicate. If two of the three values were ≤20 copies/µL, a
second sample was requested. Samples with TRECs≤5 copies/µL
(preterm infants) or ≤10 copies/µL (term newborns) in the first
sample (both with beta-actin gene ≥50 copies/µL), as well as
analyses with TRECs ≤20 copies/µL in the second sample, were
considered as positive detection (retest cutoff changed from 34 to
24 copies/µL in 2018). These positive detections were notified to
the SCID Clinical Reference Unit (SCID-CRU) to initiate clinical
and immunological evaluation.
The retest after the first sample rate (retest rate), requested
second sample rate, and SCID-positive detection rate (positive
detections) were calculated. Based on these results, the algorithm
was reevaluated. Validation of the results was carried out using
Specimen Gate (Perkin Elmer) and Nadons (Limit4, Barcelona,
Spain) software.
Initial Clinical and Immunological
Assessment at SCID-CRU
Within the first 7 days after detection, all positive cases were
referred to SCID-CRU, where clinical and immunological
assessment was performed per protocol (Figure 2).
Complete family and medical histories were recorded, and
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a meticulous physical examination was carried out. In addition,
psychological support was offered to parents, starting with this
first visit.
Several tests were performed: T, B, and NK cell
immunophenotyping, expression of CD45RA/RO, TCR αβ,
and γδ, HLA-DR+ expression on T lymphocytes, in vitro
lymphocyte proliferation, and immunoglobulins including IgE.
SCID criteria (Supplementary Material S2) were defined as
reported by Kwan et al. (2). In cases of non-SCID lymphopenia,
a consultation was scheduled with the geneticist for clinical
evaluation and array-based comparative genomic hybridization
(CGH-array) studies. If these results were normal, a genetic
panel covering most PID was performed. We used a custom-
designed next-generation sequencing (NGS)-based panel that
targets 323 genes (Supplementary Material S3), including
most of the known PID-causing genes according to the
2017 IUIS (International Union of Immunological Societies)
classification, and other genes recently described as causing
PID (20). This panel has been successfully used in our
laboratory over the last few years for genetic diagnosis of
PID (21).
Statistical Analysis
Statistical analyses were performed using SPSS software version
23.0 (SPSS Inc., Chicago, Illinois). Given the non-parametric
distribution of the data, the Mann–Whitney U or Kruskal–
Wallis test were used for group comparison analyses (25 and
75th percentiles in brackets). Two-tailed statistical analysis
was performed, and differences were considered statistically
significant at p < 0.05.
RESULTS
Demographics
Of the 129,614 newborns screened after applying the exclusion
criteria (initial n = 130,903), 51.5% were male and 48.5% were
female. The median age at sample collection was 50 h of life
(interquartile range [IQR], 49–60). Median gestational age was
39 weeks (38–40): 0.6% were extremely preterm newborns (n =
830), 5.9% preterm (n = 7,561), and 93.5% term newborns (n
= 121,223). Median birth weight in term newborns was 3,300 g
(3,010–3,590) (Table 1).
Median TREC value in the study population was 104
copies/µL (IQR: 68–162), with 20 copies/µL being the 0.7th
percentile. Median TREC values showed statistically significant
differences in relation to the patients’ sex, gestational age, and
birth weight (only assessed in term babies). Median TREC values
were 98 (64–152) and 111 (73–173) in males and females,
respectively (p < 0.05). In relation to gestational age, the
median TREC value demonstrated a progressive increase: 70 (43–
127), 96 (62–155), and 105 (68–162) copies/µL in extremely
preterm, preterm, and term newborns, respectively (p < 0.05)
(Supplementary Material S4). Regarding birth weight in term
newborns, median TREC was 94 (61–145) and 105 (69–163)
copies/µL in low and normal birth weight babies, respectively
(p < .05) (Table 1).
TABLE 1 | Demographic data and TREC values in the study population.
Sample size n = 129,614a TRECs,
copies/µL,
median (IQR)
p-valuec
All newborns 104 (68-162) –
Sex
Male 51.5% (66, 751) 98 (64–152) <0.05
Female 48.5% (62, 863) 111 (73–173)
Sample collection, hours,
median (IQR)
50 (49–60) – –
Gestational age, weeks,
median (IQR)
39 (38–40)
Extremely preterm, <32
weeks, % (n)
0.6% (830) 70 (43–127) <0.05
Preterm, 32-36 weeks, %
(n)
5.9% (7,561) 96 (62–155)
Term, ≥37 weeks, % (n) 93.5% (121, 223) 105 (68–162)
Birth weight in term
newbornsb, grams,
median (IQR):
3300 (3,010–3,590)
Low birth weight, % (n) 3.4% (4,385) 94 (61–145) <0.05
Normal weight,% (n) 96.6% (114, 777) 105 (69–163)
aSample size after applying exclusion criteria; bTerm newborns (n = 121, 223). cMann-
Whitney U or Kruskal-Wallis test were used for group comparisons (p-value calculated at
a 5% significance level). IQR, interquartile range.
Cutoff Values and Rates
The overall results from 2017 to 2018 were retest rate 2.4%,
requested second sample rate 0.23%, and positive detection rate
0.02% (Figure 3).
With the application of the initial TREC retest cutoff of 34
copies/µL (3rd percentile in the 2017 population), results from
the 66,214 samples analyzed during 2017 were as follows: retest
rate 3.34% (n = 2212), requested second sample rate 0.21% (n =
138), and positive detection rate 0.02% (n= 16).
After reducing the retest cutoff to 24 copies/µL (1st
percentile), the retest rate was 1.4% (n = 898). The detection
cutoff of 20 copies/µL remained the same (0.7th percentile), and
the requested second sample and positive detection rates were
similar to those of 2017.
Positive Detections
There were 30 positive detections in the 129,614 screened
newborns: 40% (n = 12) were detected in the first sample
and 60% (n = 18) in the second, with 50% (n = 15) of
detections occurring in males. There was no history of maternal
immunosuppression in any of the positive cases.
Newborns with positive detection were referred to the
SCID-CRU per protocol. The various diagnoses in the 30
patients were as follows (Figure 4): SCID (1/30), partial 22q11
DiGeorge syndrome (5/30), idiopathic lymphopenia (3/30),
chylothorax (2/30), prematurity (2/30), and Down syndrome
(1/30). Laboratory and clinical data of non-SCID TCL patients
are described in Table 2. Nine patients were considered to
have false-positive results (i.e., initially low TRECs and normal
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FIGURE 3 | Results of SCID NBS in Catalonia over the study period (2017–2018). 12018 cutoff (2017 cutoff = 34 copies/µL); 22017+2018-Retest rate 2017-Retest
rate = 3.34% (cutoff = 34 copies/µL); 2018-Retest rate = 1.4% (cutoff = 24 copies/µL); 3Three patients are currently under study. NB, newborns; SCID, severe
combined immunodeficiency; SCID-CRU, SCID Clinical Reference Unit.
lymphocyte count, with normalization of TRECs between 3 and
6 months of life), four patients had transient lymphopenia (i.e.,
initially low TRECs and low lymphocyte count, with recovery
in the following months), and three patients are currently
under study (SCID excluded, but requiring additional TREC
testing at 3 and 6 months of life). The incidence of clinically
significant non-SCID TCL was 1 case in 10,069 newborns (43%
of positive detections).
Thus, the incidence of SCID was 1 in 130,903 newborns.
The SCID patient was a Caucasian male of 35 weeks’ gestation
with 0/0 TREC copies/µL in DBS. Lymphocyte count was 0.4
× 109/L with a T-B- NK+ phenotype and an absent in vitro
proliferative response to mitogens. Whole exome sequencing was
performed, but no causative mutations were found. However, a
variant of uncertain significance was identified in the LIG1gene.
The patient underwent HSCT at the age of 2 months of life using
reduced intensity conditioning, with a good clinical outcome and
immunological reconstitution.
DISCUSSION
This study reports the Catalonian NBS experience for SCID
detection based on TREC quantification, and enables detection
of non-SCID lymphopenic conditions in addition to SCID. After
a 2-year experience and more than 130,000 newborns screened,
one SCID patient and 13 other conditions were identified. In
addition, we were able to consolidate our detection strategy
and the characterization, diagnosis, and follow up protocol for
positive cases.
As a pioneer initiative in Europe, we encourage the definition
of a single technical approach for SCID newborn screening to
facilitate future comparative studies between different countries.
With this in mind, we decided to implement the commercially
available EnLite Neonatal TREC kit (Perkin Elmer, Turku,
Finland), which has been validated elsewhere and has shown
comparable median TREC values between different studies (4, 6,
22, 23). This kit allows for DNA elution and gene amplification
in a single process, as well as standardization and reproducibility
according to ISO 15189 standards. With the aim of minimizing
the previously described inter-lot variability (6), we established
a retest cutoff higher than the request second sample cutoff,
which provided a range between the retest and detection cutoffs.
The initial retest cutoff was 34 copies/µL (3rd percentile),
which was changed to 24 copies/µL (1st percentile) in 2018,
whereas the request second sample cutoff was maintained at
20 copies/µL.
The initial retest cutoff of 34 copies/µL (3rd percentile)
led to a retest rate of 3.34%, which was considered too high
in comparison with data from other authors (24). Hence, we
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then evaluated the first percentile from our population (24
copies/µL) as a new retest cutoff. We found that 1,477 of
1,478 babies with initial TREC values between 34 and 25
SCID
(1/30)
Partial 22q11.2 
DiGeorge syndrome
(5/30)
Transient 
lymphopenia2
(4/30)
Idiopathic 
lymphopenia
(3/30)
Chylothorax
(2/30)
Prematurity
(2/30)
Down syndrome 
(1/30)
False positives1
(9/30)
Under study
(3/30)
FIGURE 4 | Final diagnoses in patients testing positive in Catalonia
(2017–2018). 1False-positives due to initially normal lymphocyte count with
normalization of TRECs between 3 and 6 months of life; 2Transient
lymphopenia due to initially low lymphocyte count with recovery in the
following months. Final diagnosis of the 13 non-SCID lymphopenic patients
are now boxed. SCID, severe combined immunodeficiency.
copies/µL were normal: 1,455 (98.4%) after duplicate repetition
and 22 (1.6%) after a second DBS analysis. Only one baby
within this range was referred for study in the SCID-CRU
and the diagnosis was not a case of SCID, the objective of
this screening. Following this analysis, we decided that it was
reasonable to switch to 24 copies/µL as the TREC repeat
cutoff, implemented since 2018. That change reduced the
repetition rate to 1.4%, now comparable to the rate described
by others (24) and led to a reduction in the screening cost
per patient.
Our internal algorithm showed a second sample request
rate and positive detection rate of 0.2 and 0.02%, respectively,
in keeping with the rates in previous studies, as summarized
in the review by van der Spek et al. (24). In addition, the
percentiles of our population corresponding to each cutoff are
comparable to those of other diseases included in our program,
such as congenital hypothyroidism, phenylketonuria, and other
metabolic diseases. Of note, the method was unable to adequately
quantify beta-actin copies in some of the external quality control
samples from the CDC program, a shortcoming that may
be related to PCR inhibition, as was suggested by the CDC
itself. Nonetheless, this limitation did not affect the results of
SCID screening.
Several studies have used combined TREC and KREC
screening assays to simultaneously detect T- and B-cell defects
(18, 25), including a pioneer study performed in Spain by de
Felipe et al. (26), but we decided to focus on classical SCID
patients who completely fulfill the NBS criteria, in accordance
with the experience in the United States (2, 5). Although
TABLE 2 | Clinical and laboratory data in non-SCID TCL patients.
Patient Gestational
age
Sex Prenatal
diagnosis
TREC levels
(copies/µL)
Lymphocyte
count, (x109/L)*
Lymphocyte
subsets:T cells/B
cells/NK cells
(x109/L)**
Lympho-
proliferationassay
Clinical features at
birth
Diagnosis
1 40 Female No 17 4.2 2.1/19.9/1.1 Normal None 22q11.2 DS
2 40 Female No 5 5.4 1.6/1.1/2.3 Normal None 22q11.2 DS
3 34 Female Yes 5 2.6 1.1/0.6/0.7 Normal Congenital heart disease 22q11.2 DS
4 39 Female Yes 17 2 1.9/1.4/2 Normal Congenital heart disease
and hypocalcemia due
to hypoparathyroidism
22q11.2 DS
5 41 Female No 17 1.7 1.2/0.04/0.3 Normal None 22q11.2
duplication
6 40 Male No 14 3.7 2.2/0.6/0.6 Normal None Idiopathic
lymphopenia
7 40 Male No 7 3.3 1.7/0.6/0.7 Normal None Idiopathic
lymphopenia
8 35.2 Male No 6 1.7 2/0.2/0.2 Normal None Idiopathic
lymphopenia
9 34 Female Yes 6 7.8 NA Normal Congenital Chylothorax Chylothorax
10 34 Female Yes 4 7.4 NA Normal Hydrops fetalis Chylothorax
11 32 Male No 7 2.7 2.9/0.8/0.2 Normal None Prematurity
12 29 Male No 18 4.4 2.9/1/0.2 Normal None Prematurity
13 31 Female No 15 3 NA Normal Esophageal atresia Down
syndrome
*Reference value: 3.4–7.6; **Reference values: T-cells: 1.8–5.9; B-cells: 0.6–1.9; NK-cells: 0.1–1.3. CGH, comparative genomic hybridization; DS, deletion syndrome; NA, not available;
NBS, newborn screening; SCID, severe combined immunodeficiency; TREC, T-cell receptor excision circle.
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inclusion of KREC values to the TREC assay would enable the
detection of patients with hypomorphic mutations leading to a
leaky SCID phenotype and delayed-onset adenosine deaminase
(ADA) deficiency (14, 25, 27), it might also result in an increase
in false-positive testing and higher recall and retest rates.
Our data support the previously reported influence of
gestational age and sex on TREC values (27–30). Thus, in the
case of low values in preterm babies or low-birth-weight term
newborns (i.e., TREC values above 5 copies/µL in preterm babies
and 10 copies/µL in term newborns), cautious evaluation and a
request for a second sample are needed at term and when birth
weight reaches >2,500 g, respectively. To our knowledge, there is
no explanation for the significantly higher TREC values seen in
female newborns; however, these differences have been described
previously in a cohort study reported by Rechavi et al. (4) Further
studies may provide data to define the reason for these differences
and their clinical implications, if any.
With regard to gestational age, median TREC levels in
our cohort rose significantly from 28 to 32 weeks gestation
in accordance with T-cell maturation in this period, a wider
period of time than those reported by other authors (4, 18, 26)
(Supplementary Material S4).
Overall, there were 30 positive detections in the 129,614
newborns screened (130,903 before applying the exclusion
criteria). All were referred to the SCID-CRU per protocol.
Nine patients were considered to have false-positive results due
to initially normal total lymphocyte and CD3+ counts with
normalization of TRECs between 3 and 6 months of life, whereas
four others had transient lymphopenia at the beginning with
recovery in the following months, and three are currently under
study [none of the three patients under study met the SCID
criteria, as defined by Kwan et al. (2)].
The diagnosis of the T-B-NK+ SCID patient permitted timely
referral to a specialized treatment center for HSCT, after which
T and B lymphocyte counts normalized with fully reconstituted
function, eliminating the need for IgG supplementation at 1 year
of age.
The incidence of SCID found in this study (1 in 130,903) is
lower than the reported rates from other areas (2, 4, 24). However,
we anticipate that a more robust incidence will be established
when the population analyzed reaches 200,000 newborns. In
this line, a retrospective study in our region demonstrated an
incidence of classically diagnosed SCID of 1 in 57,000 newborns
(unpublished data). In addition to the SCID patient, 13 infants
with non-SCID TCL were identified, yielding an incidence of
1 in 10,069 newborns (43% positive detections). This is similar
to the rate reported by others (31). The diagnostic distribution
was also comparable. It is worth mentioning that early detection
of patients with 22q11.2 deletion syndrome allowed a prompt
intervention to anticipate complications, as reported by our
group (Mol Genet Genomic Med, accepted).
Of note, one of the strengths of our SCID NBS approach
is the psychological support offered to the families. A positive
result in any NBS program is a cause of concern for parents
at this vulnerable time because of an unfamiliarity with these
illnesses, the young age of the patients, and the stress on families
after a birth. Therefore, in neonates initially testing positive, a
psychologist provided support starting from the first contact with
the family in a joint visit with the pediatric immunologist. The
psychologist’s task was to guarantee that parents were able to
understand and assimilate the information about the possible
diagnosis and the process to follow in the event that it was
confirmed. The family was offered a space for containment and
support for the impact of the diagnosis, and strategies were
activated to control anxiety. The psychologist maintained contact
to ensure adherence to the treatments prescribed and compliance
with the control visits and tests. Support was intensified in
the most complicated moments, such as hospital admission
and isolation, and parents were accompanied in all phases
related to transplantation. Several cases of parental anxiety were
detected and appropriately managed. In the yearly evaluation,
families rated the psychological support in our NBS program
very favorably.
The main limitation of this study is the relatively small
number of newborns screened, although the similarity between
our results and those reported in larger cohorts supports their
validity. In addition, retrospective data show an incidence of
SCID in our region similar to that of other Western European
countries (6, 18) and the United States (5).
To conclude, TREC quantification in DBS for SCID detection
has been satisfactorily implemented in the Catalonian NBS
program. Retesting, requested second samples, and positive
detection rates were optimal with the current algorithm and
similar to published data. Our results provide further evidence to
support the inclusion of SCID in NBS programs in other regions
and countries. Longer follow-up is needed to define the exact
incidence of SCID in Catalonia.
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